Short answer
Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $566.5M expected net proceeds from equity offering, materially strengthening Tango’s funding position.
Tango Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $566.5M expected net proceeds from equity offering, materially strengthening Tango’s funding position
- Proceeds intended for R&D, pivotal-trial preparation, potential commercialization, general administration, and capital expenditures
- Management expects cash runway into 2030, reducing near-term financing risk but remaining dependent on operating plans
- Offering includes 18,166,667 shares and pre-funded warrants for 1,833,395 shares, creating substantial dilution
- Underwriters hold a 30-day option for 3,000,009 additional shares, representing potential incremental dilution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tango Therapeutics, Inc. 8-K filings
Get the next TNGX 8-K as it lands
Follow TNGX for push alerts, or ask the research agent what this filing means.